REBYOTA
STN: 125739
Proper Name: fecal microbiota, live-jslm
Tradename: REBYOTA
Manufacturer: Ferring Pharmaceuticals Inc.
Indication:
- REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Product Information
Supporting Documents
- November 30, 2022 Approval Letter - REBYOTA
- November 30, 2022 Summary Basis for Regulatory Action - REBYOTA